간편하게 보는 뉴스는 유니콘뉴스
Boston Oncology and King Fahd Medical City (KFMC) Partner to Advance Localized Cell & Gene Therapy in Saudi Arabia

· 등록일 Aug. 01, 2024 15:30

· 업데이트일 2024-08-02 00:00:19

CAMBRIDGE, MASS. & RIYADH, SAUDI ARABIA--(Business Wire / Korea Newswire)--In a landmark initiative poised to transform healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a Letter of Intent to collaborate on the localization of Cell & Gene Therapy.

Representatives from Boston Oncology and King Fahd Medical City (KFMC), along with His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, at the signing ceremony for the partnership to advance localized Cell & Gene Therapy in Saudi Arabia. (Photo: Business Wire) The signing ceremony, attended by His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, marks a significant step forward in advancing the Kingdom’s medical capabilities and achieving the ambitious goals set forth in Vision 2030.

A Milestone in Healthcare Transformation

Dr. Fahad Al-Ghofaili, KFMC CEO, expressed his enthusiasm: “Localizing Cell & Gene Therapy in KFMC is an important step to increase local capabilities in advanced treatments and medical technologies, contributing to the goals of the Healthcare Transformation Project.” [Translated from Arabic]

Impact for Patients

Boston Oncology, renowned for its customer-centered model, brings extensive expertise in localizing technology. Laser-focused on the real-world needs of patients and hospitals, Boston Oncology is positioned to provide cutting-edge technologies and Cell & Gene Therapies through this partnership. This collaboration will establish a local treatment option, relieving bottlenecks in therapy provision and improving patient outcomes. The resulting Research & Development and clinical trials will significantly contribute to innovative advancements in the healthcare sector of Saudi Arabia.

Dr. Abdullah Baaj, CEO of Boston Oncology, described the partnership: “KFMC brings world-class clinicians and infrastructure, making it a destination for patients throughout the region. Joining forces to localize Cell & Gene Therapy is a transformative step towards our mission to impact the lives of one billion patients.”

About Boston Oncology Cell & Gene Therapy

Boston Oncology is an innovative life science company with a mission to impact the lives of one billion patients by 2030. With corporate headquarters in Cambridge, Massachusetts, and operations throughout the world, the company is focused on bringing patient-centered solutions and advanced treatment modalities to growing markets. Its new Cell & Gene Therapy entity establishes a fully localized offering to deliver personalized treatments that address the unique genetic profiles of patients. By partnering with leading medical institutions and leveraging leading-edge technologies, Boston Oncology CGT is expanding the company’s legacy of transformative advancements in healthcare.

Learn more at https://bostononcology.com/.

About King Fahd Medical City

King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia, stands as one of the largest and most rapidly expanding medical complexes in the Middle East, with a capacity of 1,200 beds. Operating within the second health cluster, KFMC consists of four hospitals and four specialized medical centers, offering comprehensive healthcare services. Known for its advanced medical technologies and high standard of care, KFMC serves over 30,000 inpatients and 500,000 outpatients annually. The institution is committed to excellence in clinical services, medical education, research, and continuous improvement in healthcare.

Learn more at https://www.kfmc.med.sa/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731424463/en/

Website: https://bostononcology.com/ Contact Boston Oncology
Public Relations
[email protected]
This news is a press release provided by Boston Oncology. Korea Newswire follows these editorial guidelines. Boston Oncology News ReleasesSubscribeRSS 보스턴 온콜로지-킹 파흐드 메디컬 시티, 사우디에서 세포·유전자 치료 현지화의 발전 위해 파트너십 체결 보스턴 온콜로지(Boston Oncology)와 킹 파흐드 메디컬 시티(King Fahd Medical City, KFMC)가 세포 및 유전자 치료의 현지화에 대한 협력 의향서에 서명하면서 사우디아라비아의 의료 혁신을 위한 기념비적 이니셔티브를 시작했다. 압둘라지즈 알라마이흐 보건부 기획개발 차관(His Excellency Eng. Abdulazi... 8월 1일 15:30 More News Health Biotechnology Pharmaceutical Alliance Overseas Boston Oncology All News Releases 
인기 기사06.08 04시 기준
UTRECHT, NETHERLANDS--(Business Wire / Korea Newswire)--Following the Lisk blockchain upgrade to the Optimism Superchain this week, Dutch startup Klayr Labs announced it would be taking over the Layer 1 technology and starting a new...
서울--(뉴스와이어)--오픈AI 및 구글, 마이크로소프트 등을 중심으로 생성형 AI 시대가 활짝 열린 가운데 기업 운영에 생성형 AI를 효과적으로 도입하기 위해 반드시 참고해야 하는 리포트가 나와 눈길을 끈다. 한국 딜로이트 그룹은 올해 1월부터 2월까지 6개 국가...
웨인, 펜실베이니아--(Business Wire / 뉴스와이어)--신경 복구 및 재생 분야의 선두 주자인 뉴랩티브 세라퓨틱스(Neuraptive Therapeutics, Inc.)가 말초 신경 손상에 대한 치료 패러다임을 변화시키는 데 중요한 이정표를 발표했다. NTX-001의 NEUROFUSE 임상시험에서 개념 증명의 성공적인 시연은 말초...
서울--(뉴스와이어)--언어 데이터 및 전문번역 서비스 기업 플리토(대표 이정수, 코스닥 300080)가 여성가족부 주관 ‘가족친화기업’ 인증을 처음으로 획득했다고 28일 밝혔다. 가족친화기업 인증은 여성가족부가 ‘가족친화기업’, ‘가족친화 사회환경의 조성 촉진에 관한 법률’에 따라 자녀출산 및 양육지원, 유연근무제도 등...
NEW YORK--(Business Wire / Korea Newswire)--Uptime Institute today announced the release of its 14th Annual Global Data Center survey. The increased demand for digital services with both volume and compute intensity is challenging the...
서울--(뉴스와이어)--동원산업(대표이사 민은홍)이 지난 3일 서울시 여의도 콘래드 호텔에서 진행된 ‘제3회 MSC코리아 어워즈’에서 수산 부문 지속가능경영 성과를 인정받아 3회 연속 ‘올해의 기업상’을 수상했다고 4일 밝혔다. 서울...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.